Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1544394/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576090124582912 |
|---|---|
| author | Toshio Shimizu Toshio Shimizu John Powderly Albiruni Abdul Razak Patricia LoRusso Kathy D. Miller Steven Kao Sarah Kongpachith Catherine Tribouley Michelle Graham Brian Stoll Maulik Patel Mohammad Sahtout Martha Blaney Rachel Leibman Talia Golan Talia Golan Anthony Tolcher |
| author_facet | Toshio Shimizu Toshio Shimizu John Powderly Albiruni Abdul Razak Patricia LoRusso Kathy D. Miller Steven Kao Sarah Kongpachith Catherine Tribouley Michelle Graham Brian Stoll Maulik Patel Mohammad Sahtout Martha Blaney Rachel Leibman Talia Golan Talia Golan Anthony Tolcher |
| author_sort | Toshio Shimizu |
| collection | DOAJ |
| format | Article |
| id | doaj-art-5f3c16071ab840e8b2438f8ad9c7e71f |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-5f3c16071ab840e8b2438f8ad9c7e71f2025-01-31T11:20:08ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.15443941544394Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumorsToshio Shimizu0Toshio Shimizu1John Powderly2Albiruni Abdul Razak3Patricia LoRusso4Kathy D. Miller5Steven Kao6Sarah Kongpachith7Catherine Tribouley8Michelle Graham9Brian Stoll10Maulik Patel11Mohammad Sahtout12Martha Blaney13Rachel Leibman14Talia Golan15Talia Golan16Anthony Tolcher17Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, JapanDepartment of New Experimental Therapeutics and International Cancer New Drug Development Center, Kansai Medical University Hospital, Osaka, JapanCarolina BioOncology Institute, Huntersville, NC, United StatesCancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, Toronto, ON, CanadaYale Cancer Center, Yale University, New Haven, CT, United StatesDepartment of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United StatesDepartment of Medical Oncology, Chris O’Brien Lifehouse, Sydney, NSW, AustraliaAbbVie Bay Area, South San Francisco, CA, United StatesAbbVie Bay Area, South San Francisco, CA, United StatesAbbVie Bay Area, South San Francisco, CA, United StatesAbbVie Bay Area, South San Francisco, CA, United StatesAbbVie Bay Area, South San Francisco, CA, United StatesAbbVie Bay Area, South San Francisco, CA, United StatesAbbVie Bay Area, South San Francisco, CA, United StatesAbbVie Bay Area, South San Francisco, CA, United StatesInstitute of Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel0Oncology Institute, Sheba Medical Center at Tel-Hashomer, Tel Aviv University, Tel Aviv, Israel1New Experimental Therapeutics (NEXT) Oncology, San Antonio, TX, United Stateshttps://www.frontiersin.org/articles/10.3389/fonc.2024.1544394/fulladvanced solid tumorsTGF-ß1GARPimmunotherapyanti-PD-1 antibodycombination drug therapy |
| spellingShingle | Toshio Shimizu Toshio Shimizu John Powderly Albiruni Abdul Razak Patricia LoRusso Kathy D. Miller Steven Kao Sarah Kongpachith Catherine Tribouley Michelle Graham Brian Stoll Maulik Patel Mohammad Sahtout Martha Blaney Rachel Leibman Talia Golan Talia Golan Anthony Tolcher Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors Frontiers in Oncology advanced solid tumors TGF-ß1 GARP immunotherapy anti-PD-1 antibody combination drug therapy |
| title | Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors |
| title_full | Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors |
| title_fullStr | Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors |
| title_full_unstemmed | Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors |
| title_short | Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors |
| title_sort | corrigendum first in human phase 1 dose escalation results with livmoniplimab an antibody targeting the garp tgf ss1 complex as monotherapy and in combination with the anti pd 1 antibody budigalimab in patients with advanced solid tumors |
| topic | advanced solid tumors TGF-ß1 GARP immunotherapy anti-PD-1 antibody combination drug therapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1544394/full |
| work_keys_str_mv | AT toshioshimizu corrigendumfirstinhumanphase1doseescalationresultswithlivmoniplimabanantibodytargetingthegarptgfß1complexasmonotherapyandincombinationwiththeantipd1antibodybudigalimabinpatientswithadvancedsolidtumors AT toshioshimizu corrigendumfirstinhumanphase1doseescalationresultswithlivmoniplimabanantibodytargetingthegarptgfß1complexasmonotherapyandincombinationwiththeantipd1antibodybudigalimabinpatientswithadvancedsolidtumors AT johnpowderly corrigendumfirstinhumanphase1doseescalationresultswithlivmoniplimabanantibodytargetingthegarptgfß1complexasmonotherapyandincombinationwiththeantipd1antibodybudigalimabinpatientswithadvancedsolidtumors AT albiruniabdulrazak corrigendumfirstinhumanphase1doseescalationresultswithlivmoniplimabanantibodytargetingthegarptgfß1complexasmonotherapyandincombinationwiththeantipd1antibodybudigalimabinpatientswithadvancedsolidtumors AT patricialorusso corrigendumfirstinhumanphase1doseescalationresultswithlivmoniplimabanantibodytargetingthegarptgfß1complexasmonotherapyandincombinationwiththeantipd1antibodybudigalimabinpatientswithadvancedsolidtumors AT kathydmiller corrigendumfirstinhumanphase1doseescalationresultswithlivmoniplimabanantibodytargetingthegarptgfß1complexasmonotherapyandincombinationwiththeantipd1antibodybudigalimabinpatientswithadvancedsolidtumors AT stevenkao corrigendumfirstinhumanphase1doseescalationresultswithlivmoniplimabanantibodytargetingthegarptgfß1complexasmonotherapyandincombinationwiththeantipd1antibodybudigalimabinpatientswithadvancedsolidtumors AT sarahkongpachith corrigendumfirstinhumanphase1doseescalationresultswithlivmoniplimabanantibodytargetingthegarptgfß1complexasmonotherapyandincombinationwiththeantipd1antibodybudigalimabinpatientswithadvancedsolidtumors AT catherinetribouley corrigendumfirstinhumanphase1doseescalationresultswithlivmoniplimabanantibodytargetingthegarptgfß1complexasmonotherapyandincombinationwiththeantipd1antibodybudigalimabinpatientswithadvancedsolidtumors AT michellegraham corrigendumfirstinhumanphase1doseescalationresultswithlivmoniplimabanantibodytargetingthegarptgfß1complexasmonotherapyandincombinationwiththeantipd1antibodybudigalimabinpatientswithadvancedsolidtumors AT brianstoll corrigendumfirstinhumanphase1doseescalationresultswithlivmoniplimabanantibodytargetingthegarptgfß1complexasmonotherapyandincombinationwiththeantipd1antibodybudigalimabinpatientswithadvancedsolidtumors AT maulikpatel corrigendumfirstinhumanphase1doseescalationresultswithlivmoniplimabanantibodytargetingthegarptgfß1complexasmonotherapyandincombinationwiththeantipd1antibodybudigalimabinpatientswithadvancedsolidtumors AT mohammadsahtout corrigendumfirstinhumanphase1doseescalationresultswithlivmoniplimabanantibodytargetingthegarptgfß1complexasmonotherapyandincombinationwiththeantipd1antibodybudigalimabinpatientswithadvancedsolidtumors AT marthablaney corrigendumfirstinhumanphase1doseescalationresultswithlivmoniplimabanantibodytargetingthegarptgfß1complexasmonotherapyandincombinationwiththeantipd1antibodybudigalimabinpatientswithadvancedsolidtumors AT rachelleibman corrigendumfirstinhumanphase1doseescalationresultswithlivmoniplimabanantibodytargetingthegarptgfß1complexasmonotherapyandincombinationwiththeantipd1antibodybudigalimabinpatientswithadvancedsolidtumors AT taliagolan corrigendumfirstinhumanphase1doseescalationresultswithlivmoniplimabanantibodytargetingthegarptgfß1complexasmonotherapyandincombinationwiththeantipd1antibodybudigalimabinpatientswithadvancedsolidtumors AT taliagolan corrigendumfirstinhumanphase1doseescalationresultswithlivmoniplimabanantibodytargetingthegarptgfß1complexasmonotherapyandincombinationwiththeantipd1antibodybudigalimabinpatientswithadvancedsolidtumors AT anthonytolcher corrigendumfirstinhumanphase1doseescalationresultswithlivmoniplimabanantibodytargetingthegarptgfß1complexasmonotherapyandincombinationwiththeantipd1antibodybudigalimabinpatientswithadvancedsolidtumors |